Rivoceranib

Generic Name: Rivoceranib

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₃N_₅O

CAS Number: 811803-05-1

Unique Ingredient Identifier: 5S371K6132

Background: Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

Indication: 本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。

Clinical Trials

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Phase 2

Not yet recruiting

Conditions: Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: RC48
Drug: Adebrelimab
Drug: Apatinib
Drug: S-1

First Posted Date: 2024-04-26

Last Posted Date: 2024-05-13

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 32

Registration Number: NCT06385873

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

Phase 3

Recruiting

Conditions: Locally Advanced or Metastatic GC and GCJ Adenocarcinoma

Interventions: Drug: LM-302
Drug: Apatinib
Drug: Irinotecan

First Posted Date: 2024-04-08

Last Posted Date: 2024-07-01

Lead Sponsor: LaNova Medicines Zhejiang Co., Ltd.

Target Recruit Count: 375

Registration Number: NCT06351020

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Phase 3

Recruiting

Conditions: Gastric Cancer
Gastroesophageal Junction Cancer

Interventions: Drug: AZD0901
Drug: Ramucirumab+ paclitaxel
Drug: Paclitaxel
Drug: Docetaxel
Drug: Irinotecan
Drug: TAS-102
Drug: Apatinib

First Posted Date: 2024-04-04

Last Posted Date: 2025-05-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 589

Registration Number: NCT06346392

Locations: 🇻🇳
Research Site, Vinh, Vietnam

A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer

Phase 2

Not yet recruiting

Conditions: Advanced Breast Cancer

Interventions: Drug: apatinib mesylate+Capecitabine Tablets
Drug: apatinib mesylate+Fulvestrant injection

First Posted Date: 2024-04-01

Last Posted Date: 2024-04-19

Lead Sponsor: Li Huiping

Target Recruit Count: 68

Registration Number: NCT06339281

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Interventions: Drug: Adebrelimab
Drug: Apatinib
Drug: Tegafur

First Posted Date: 2024-04-01

Last Posted Date: 2024-04-01

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 32

Registration Number: NCT06339619

Locations: 🇨🇳
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

Phase 2

Withdrawn

Conditions: Metastatic Olfactory Neuroblastoma
Recurrent Olfactory Neuroblastoma

Interventions: Drug: Rivoceranib

First Posted Date: 2024-03-13

Last Posted Date: 2025-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 16

Registration Number: NCT06308575

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC

Phase 2

Recruiting

Conditions: Intrahepatic Cholangiocarcinoma

Interventions: Procedure: HAIC
Drug: Adebrelimab
Drug: Apatinib

First Posted Date: 2024-03-06

Last Posted Date: 2024-04-17

Lead Sponsor: Lei ZHAO

Target Recruit Count: 20

Registration Number: NCT06296563

Locations: 🇨🇳
Shandong Cancer Hospital and Institute, Jinan, Shandong, China

Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma
Efficacy
Toxicity

Interventions: Drug: Induction Immunotherapy-Toripalimab
Drug: Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin
Radiation: Radiotherapy
Drug: Apatinib
Drug: Capecitabine

First Posted Date: 2024-02-28

Last Posted Date: 2024-02-28

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 170

Registration Number: NCT06281886

Locations: 🇨🇳
Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Phase 3

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Capecitabine tablets
Drug: Fluzoparib
Drug: Vinorelbine Tartrate Oral
Drug: Apatinib Mesylate
Drug: Eribulin mesylate injection
Drug: Gemcitabine Hydrochloride
Drug: Paclitaxel-albumin

First Posted Date: 2024-02-13

Last Posted Date: 2024-02-13

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 200

Registration Number: NCT06255392

Locations: 🇨🇳
Sun Yat Sen Memorial Hospital，Sun Yat sen University, Guangzhou, Guangdong, China

First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC

Phase 2

Completed

Conditions: Advanced Gastric Adenocarcinoma

Interventions: Drug: Apatinib Combined With Tislelizumab and Chemotherapy

First Posted Date: 2024-02-02

Last Posted Date: 2024-02-02

Lead Sponsor: Renmin Hospital of Wuhan University

Target Recruit Count: 33

Registration Number: NCT06238752

Locations: 🇨🇳
Renmin hosptial of Wuhan University, Wuhan, Hubei, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy